Chieh-I Chen

1.2k total citations
9 papers, 168 citations indexed

About

Chieh-I Chen is a scholar working on Rheumatology, Epidemiology and Oncology. According to data from OpenAlex, Chieh-I Chen has authored 9 papers receiving a total of 168 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Rheumatology, 3 papers in Epidemiology and 2 papers in Oncology. Recurrent topics in Chieh-I Chen's work include Rheumatoid Arthritis Research and Therapies (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Nonmelanoma Skin Cancer Studies (2 papers). Chieh-I Chen is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Nonmelanoma Skin Cancer Studies (2 papers). Chieh-I Chen collaborates with scholars based in United States, France and United Kingdom. Chieh-I Chen's co-authors include Li Wang, Wenhui Wei, Kristine Phillips, Hüseyin Yüce, Keith Knapp, Sergio Schwartzman, Christine L. Thompson, Roger R. Dmochowski, J. Quentin Clemens and Christopher Sexton and has published in prestigious journals such as Journal of Clinical Oncology, Urology and Obstetrical & Gynecological Survey.

In The Last Decade

Chieh-I Chen

8 papers receiving 165 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chieh-I Chen United States 6 113 48 34 33 29 9 168
Heleen van Dongen Netherlands 12 108 1.0× 45 0.9× 7 0.2× 68 2.1× 17 0.6× 22 633
С. Р. Варфоломеева Russia 8 27 0.2× 16 0.3× 30 0.9× 34 1.0× 50 1.7× 118 226
Tamami Yoshitama Japan 8 133 1.2× 40 0.8× 22 0.6× 61 1.8× 19 0.7× 16 204
Karen Salomon-Escoto United States 8 119 1.1× 41 0.9× 14 0.4× 40 1.2× 10 0.3× 12 178
Kamran Naraghi United Kingdom 8 69 0.6× 43 0.9× 25 0.7× 17 0.5× 12 0.4× 15 158
Patrícia Nero Portugal 8 126 1.1× 54 1.1× 24 0.7× 29 0.9× 8 0.3× 24 185
Brigitte Krummel-Lorenz Germany 3 153 1.4× 59 1.2× 27 0.8× 52 1.6× 20 0.7× 3 216
Kathrine Lederballe Grøn Denmark 7 117 1.0× 72 1.5× 14 0.4× 52 1.6× 11 0.4× 14 161
Francesco Clemente Italy 7 29 0.3× 34 0.7× 6 0.2× 6 0.2× 32 1.1× 19 120
Maura Couto Portugal 7 128 1.1× 145 3.0× 12 0.4× 27 0.8× 25 0.9× 20 230

Countries citing papers authored by Chieh-I Chen

Since Specialization
Citations

This map shows the geographic impact of Chieh-I Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chieh-I Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chieh-I Chen more than expected).

Fields of papers citing papers by Chieh-I Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chieh-I Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chieh-I Chen. The network helps show where Chieh-I Chen may publish in the future.

Co-authorship network of co-authors of Chieh-I Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Chieh-I Chen. A scholar is included among the top collaborators of Chieh-I Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chieh-I Chen. Chieh-I Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Lim, Annette M., Sandro Porceddu, Fiona Day, et al.. (2025). Patient-reported outcomes (PROs) in the C-POST trial of adjuvant cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).. Journal of Clinical Oncology. 43(16_suppl). 6065–6065.
2.
Migden, Michael R., Sunandana Chandra, Guilherme Rabinowits, et al.. (2020). CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncology. 16(4). 11–19. 28 indexed citations
3.
Fournier, Marie, Chieh-I Chen, Andreas Kuznik, et al.. (2019). <p>Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient</p>. ClinicoEconomics and Outcomes Research. Volume 11. 117–128. 7 indexed citations
4.
5.
Muszbek, N., Clare Proudfoot, Marie Fournier, et al.. (2019). Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Journal of Managed Care & Specialty Pharmacy. 25(11). 1268–1280. 1 indexed citations
6.
Chen, Chieh-I, Li Wang, Wenhui Wei, Hüseyin Yüce, & Kristine Phillips. (2018). Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. Rheumatology Advances in Practice. 2(1). rky005–rky005. 45 indexed citations
7.
8.
Coyne, Karin S., Christopher Sexton, J. Quentin Clemens, et al.. (2013). The Impact of OAB on Physical Activity in the United States: Results from OAB-POLL. Urology. 82(4). 799–806. 32 indexed citations
9.
Coyne, Karin S., Christopher Sexton, Jill A. Bell, et al.. (2013). The Prevalence of Lower Urinary Tract Symptoms (LUTS) and Overactive Bladder(OAB) by Racial/Ethnic Group and Age. Obstetrical & Gynecological Survey. 68(9). 627–628. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heleen van Dongen Breakdown of academic impact, for papers by С. Р. Варфоломеева Breakdown of academic impact, for papers by Tamami Yoshitama Breakdown of academic impact, for papers by Karen Salomon-Escoto Breakdown of academic impact, for papers by Kamran Naraghi Breakdown of academic impact, for papers by Patrícia Nero Breakdown of academic impact, for papers by Brigitte Krummel-Lorenz Breakdown of academic impact, for papers by Kathrine Lederballe Grøn Breakdown of academic impact, for papers by Francesco Clemente Breakdown of academic impact, for papers by Maura Couto
Rankless by CCL
2026